Biologics API MarketSize, Share & Industry Analysis, 2026-2034By Molecule TypeBy Expression SystemBy SourceBy Manufacturing ModeBy Scale of OperationBy Process TypeBy Bioreactor TechnologyBy Therapeutic AreaBy Route of AdministrationBy End User
Full title & scope — all 10 axes with their segments
Biologics API Market Size, Share & Industry Analysis, By Molecule Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell and Gene Therapy, Peptides and Oligonucleotides, Plasma-Derived Products), By Expression System (Mammalian Cells, Microbial, Insect Cells, Plant-Based, Cell-Free), By Source (Innovator Biologics, Biosimilars), By Manufacturing Mode (In-House Manufacturing, Outsourced), By Scale of Operation (Preclinical, Clinical, Commercial), By Process Type (Batch, Fed-Batch, Perfusion and Continuous), By Bioreactor Technology (Single-Use Systems, Stainless Steel Systems), By Therapeutic Area (Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, Metabolic Disorders, Neurology, Rare and Genetic Diseases), By Route of Administration (Injectable, Oral, Inhalation, Topical), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic and Research Institutes), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By Molecule TypeMonoclonal Antibodies · Recombinant Proteins · Vaccines
- 02By Expression SystemMammalian Cells · Microbial · Insect Cells
- 03By SourceInnovator Biologics · Biosimilars
- 04By Manufacturing ModeIn-House Manufacturing · Outsourced
- 05By Scale of OperationPreclinical · Clinical · Commercial
- 06By Process TypeBatch · Fed-Batch · Perfusion and Continuous
- 07By Bioreactor TechnologySingle-Use Systems · Stainless Steel Systems
- 08By Therapeutic AreaOncology · Autoimmune and Inflammatory Diseases · Infectious Diseases
- 09By Route of AdministrationInjectable · Oral · Inhalation
- 10By End UserPharmaceutical Companies · Biotechnology Companies · Contract Development and Manufacturing Organizations
- 11By Region
Market Analysis & Outlook
Biologics APIs are the bulk active substances of drugs made in living systems, including antibodies, recombinant proteins, vaccines, cell and gene therapy materials, peptides and plasma-derived fractions, before they are formulated into finished doses. They are produced in cell culture or microbial fermentation and purified under tightly controlled conditions. Buyers are pharmaceutical and biotechnology companies, the contract manufacturers that supply them, and research institutes.
The global biologics api market is valued at USD 70 billion in 2025 and is set to reach USD 138.6 billion by 2034, a compound annual growth rate of 7.8% across the 2026-2034 forecast period. The study tracks the market across USD 43 billion in 2020, USD 64.5 billion in 2024, USD 76 billion in 2026 and USD 104 billion in 2030.
46% of 2025 revenue sits in Monoclonal Antibodies, worth USD 32.2 billion and rising to USD 60.98 billion at 44% by 2034, the largest molecule type line in both years. Growth is fastest in Cell and Gene Therapy at 19.84% and slowest in Plasma-Derived Products at 4.32%. The lines gaining share are Cell and Gene Therapy and Peptides and Oligonucleotides. Monoclonal Antibodies, Recombinant Proteins, Vaccines and Plasma-Derived Products lose share without losing revenue.
The expression system split puts Mammalian Cells first, at USD 44.8 billion and 64% of revenue in 2025, rising to USD 85.94 billion and 62% in 2034. Cell-Free grows faster at 16.51% against 7.51%, moving from 2% of revenue to 4% by 2034. It cuts the same total as the molecule type axis from a different commercial angle, so revenue does not add across the two.
USD 29.4 billion of 2025 revenue is generated in North America, 42% of the global total and the largest regional share; it reaches USD 53.22 billion by 2034. Europe is next at 27% and USD 18.9 billion, and Middle East and Africa last at 2.8%. Share shifts toward Asia Pacific and Middle East and Africa over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, six molecule type lines and ten segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global biologics api market moves from USD 43 billion in 2020 to USD 70 billion in 2025 and USD 138.6 billion by 2034, the forecast period compounding at 7.8% a year.
- The largest line by molecule type is Monoclonal Antibodies, worth USD 32.2 billion and 46% of revenue in 2025, rising to USD 60.98 billion and 44% by 2034.
- Fastest growth on the molecule type axis belongs to Cell and Gene Therapy: 19.84% a year, USD 3.5 billion to USD 19.4 billion, and a share moving from 5% to 14%.
- Against a base case of USD 138.6 billion in 2034, the study also reports a bear case at USD 119.89 billion and a bull case at USD 153.57 billion, with the assumptions behind each set out separately.
- 42% of 2025 revenue is generated in North America, worth USD 29.4 billion and rising to USD 53.22 billion by 2034; Middle East and Africa is smallest at 2.8%.
- Within North America, the United States is the worked country example, at USD 27 billion in 2025; 91.84% of regional revenue in the base year, and USD 48.7 billion by 2034.
- Every line on all ten segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By molecule type
Base year 2025Monoclonal Antibodies leads with 46.0% of molecule type segment revenue.
Share of molecule type segment revenue, most recent base year.
The global biologics api market is shaped over 2026-2034 by three measurable movements: a change in the molecule type mix, a shift in where revenue sits geographically, and the 7.8% rate carrying the total.
The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.
Composition shifts on the molecule type axis. Cell and Gene Therapy grows at 19.84% across 2026-2034 against 4.32% for Plasma-Derived Products, the widest spread on the molecule type axis. Shares follow: 5% to 14% for Cell and Gene Therapy, 8% to 6% for Plasma-Derived Products. Revenue rises on both sides; USD 3.5 billion to USD 19.4 billion and USD 5.6 billion to USD 8.32 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Growth concentrates in Asia Pacific and Middle East and Africa. Asia Pacific moves from 24% of revenue in 2025 to 29.4% in 2034, worth USD 16.8 billion rising to USD 40.74 billion; Middle East and Africa moves from 2.8% of revenue in 2025 to 3.1% in 2034, worth USD 1.96 billion rising to USD 4.3 billion. The offsetting side is North America at 42% moving to 38.4%, Europe at 27% moving to 25.2%, Latin America at 4.2% moving to 3.9%, none of which contracts. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.
Fifteen years without a discontinuity. Fifteen years of revenue run USD 43 billion in 2020, USD 64.5 billion in 2024, USD 70 billion in 2025, USD 76 billion in 2026, USD 104 billion in 2030 and USD 138.6 billion in 2034. There is no discontinuity to time, and 7.8% forecast growth against 10.24% historical means the trend continues and does not turn. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the molecule type and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
19.84% growth in Cell and Gene Therapy, against 7.8% for the market as a whole, moves it from USD 3.5 billion and 5% of revenue in 2025 to USD 19.4 billion and 14% in 2034. Because the spread to Plasma-Derived Products at 4.32% is this wide, the headline 7.8% is a weighted result, not a rate any single line achieves. Exposure to this line, not to the market as a whole, is what determines a supplier's own rate.
- 02Regional weight, not regional count
42% of 2025 revenue (USD 29.4 billion) is generated in North America, reaching USD 53.22 billion by 2034 at an unchanged 38.4%. Europe adds a further 27% at USD 18.9 billion, reaching USD 34.93 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03The trend is already in the record
The historical period compounded at 10.24%; USD 43 billion in 2020, USD 64.5 billion in 2024 and USD 70 billion in 2025. The forecast continues at 7.8% to USD 138.6 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7.8% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Expanding approved and late-stage biologics pipeline | High | +28 | High | High | Medium |
| 2 | Biosimilar uptake as originator patents lapse | High | +20 | High | High | Medium |
| 3 | Outsourcing of drug substance manufacturing to contract sites | Medium-High | +14 | High | Medium | Medium |
| 4 | Cell and gene therapy and other advanced modalities reaching commercial scale | Medium-High | +10 | Low | Medium | High |
| 5 | Single-use and continuous process adoption lifting plant output | Medium | +6 | Medium | Medium | Medium |
| 6 | Others | Low | +5 | Low | Low | Low |
| Total | +83 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High capital cost and long qualification lead times for new capacity | High | −8 | High | Medium | Medium |
| 2 | Price pressure from biosimilar competition and payer reimbursement limits | Medium | −4.5 | Medium | High | High |
| 3 | Shortages of skilled staff and specialised raw materials | Low | −2 | Medium | Low | Low |
| Total | −14.5 | |||||
Drivers contribute 83 USD Billion and restraints remove 14.5 USD Billion, a net 68.5 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Three sources account for the growth to 2034: 7.8% compounding across the base, share moving toward the faster molecule type lines, and above-market expansion in the leading regions.
Restraining Factors
Downside case: USD 119.89 billion by 2034, against USD 138.6 billion in the base case
Market Restraints
2- 01Downside case: USD 119.89 billion by 2034, against USD 138.6 billion in the base case
Capacity delays, tighter biosimilar pricing and clinical setbacks in newer modalities slow orders and hold utilisation below plan. On that assumption 2034 revenue lands at USD 119.89 billion against the USD 138.6 billion base case, from the same USD 70 billion 2025 starting point.
- 02Monoclonal Antibodies grows below the market rate
Monoclonal Antibodies carries 46% of 2025 revenue at USD 32.2 billion but compounds at 7.26% against 7.8% for the market, taking its share to 44% by 2034 even as revenue rises to USD 60.98 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
Approvals run ahead of the recorded rate, contract capacity arrives on schedule and biosimilar uptake accelerates as more originator patents lapse. On that assumption the market reaches USD 153.57 billion by 2034 against USD 138.6 billion in the base case, from the same USD 70 billion in 2025.
- 02Cell and Gene Therapy share moves from 5% to 14%
Cell and Gene Therapy grows at 19.84% against 7.8% for the market, adding revenue from USD 3.5 billion in 2025 to USD 19.4 billion in 2034 and taking its share from 5% to 14%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Monoclonal Antibodies.
Market Challenges
Revenue is concentrated in Monoclonal Antibodies
Market Challenges
2- 01Revenue is concentrated in Monoclonal Antibodies
With 46% of 2025 revenue and 44% of 2034 revenue (USD 32.2 billion rising to USD 60.98 billion) Monoclonal Antibodies is where the market's exposure sits. No other single change on the molecule type axis moves the total as much as a change in demand for that one line.
- 02One country drives the leading region
Of North America's USD 29.4 billion in 2025, USD 27 billion (91.84%) comes from the United States alone, rising to USD 48.7 billion by 2034. Regional totals therefore move largely with one country's demand, so a regional forecast is more exposed to single-country conditions than its size alone suggests.
Segmentation Analysis
10 axesThe global biologics api market is cut ten ways: by molecule type, expression system, source, manufacturing mode, scale of operation, process type, bioreactor technology, therapeutic area, route of administration and end user. Every one of them divides the same revenue, which makes them views of one market from different commercial angles, not components of it.
Six molecule type lines are reported. Two of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Molecule Type · 6 segments
Cell and Gene Therapy Outpaces the Axis While Monoclonal Antibodies Holds the Largest Share
- Largest Monoclonal Antibodies · 46%
- Fastest Cell and Gene Therapy · 19.8%
- Moves most Cell and Gene Therapy · +9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Monoclonal Antibodies | $32.20B | 46% | $60.98B | 44%-2 | 7.3% |
| Recombinant Proteins | $12.60B | 18% | $19.40B | 14%-4 | 4.8% |
| Vaccines | $9.80B | 14% | $15.25B | 11%-3 | 4.9% |
| Cell and Gene Therapy | $3.50B | 5% | $19.40B | 14%+9 | 19.8% |
| Peptides and Oligonucleotides | $6.30B | 9% | $15.25B | 11%+2 | 10.2% |
| Plasma-Derived Products | $5.60B | 8% | $8.32B | 6%-2 | 4.3% |
Monoclonal antibodies lead because the approved therapeutic pipeline is deepest in this class, commercial lots are large, and a long list of marketed products keeps ordering steady. Cell and gene therapy grows fastest from a small base as more programmes move from clinical trials to launch and each new approval adds dedicated vector and cell-line material demand. Monoclonal Antibodies remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Expression System · 5 segments
Mammalian Cells Led by Expression system in 2025, with Cell-Free Growing Fastest
- Largest Mammalian Cells · 64%
- Fastest Cell-Free · 16.5%
- Moves most Microbial · -3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Mammalian Cells | $44.80B | 64% | $85.94B | 62%-2 | 7.5% |
| Microbial | $17.50B | 25% | $30.49B | 22%-3 | 6.4% |
| Insect Cells | $4.90B | 7% | $12.47B | 9%+2 | 10.9% |
| Plant-Based | $1.40B | 2% | $4.16B | 3%+1 | 12.9% |
| Cell-Free | $1.40B | 2% | $5.54B | 4%+2 | 16.5% |
Mammalian cell systems lead because most antibodies and complex glycosylated proteins need human-like folding and modification, and regulators know these platforms well. Cell-free systems grow fastest from a very small base, as developers adopt them for rapid, small-batch and difficult-to-express targets where speed to a first lot matters more than volume. The order does not change: Mammalian Cells is still largest in 2034, and what moves is how much it holds.
By Source · 2 segments
Scale in Innovator Biologics and Growth in Biosimilars Define the Source Axis
- Largest Innovator Biologics · 72%
- Fastest Biosimilars · 11.6%
- Moves most Innovator Biologics · -10 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Innovator Biologics | $50.40B | 72% | $85.93B | 62%-10 | 6.1% |
| Biosimilars | $19.60B | 28% | $52.67B | 38%+10 | 11.6% |
Innovator biologics lead because originator products still hold most of the high-value therapeutic sales and the largest commercial lots. Biosimilars grow fastest as patents lapse on large antibody and insulin franchises, regulators have settled interchangeability pathways, and health systems push for lower-cost alternatives that expand the number of treated patients. By 2034 Innovator Biologics is still ahead, making this a shift in weight, not a change of leader.
By Manufacturing Mode · 2 segments
Scale in In-House Manufacturing and Growth in Outsourced (CDMO) Define the Manufacturing mode Axis
- Largest In-House Manufacturing · 66%
- Fastest Outsourced (CDMO) · 10.7%
- Moves most In-House Manufacturing · -9 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| In-House Manufacturing | $46.20B | 66% | $79B | 57%-9 | 6.1% |
| Outsourced (CDMO) | $23.80B | 34% | $59.60B | 43%+9 | 10.7% |
In-house manufacturing leads because large originators own their commercial plants and keep process knowledge close for products with long lifecycles. Outsourced manufacturing grows fastest as smaller developers lack capital for their own suites, and larger firms use contract capacity to add flexibility for new launches without waiting years for a plant to be built. In-House Manufacturing remains the largest line through 2034, so the axis changes in proportion, not in order.
By Scale of Operation · 3 segments
Scale and Growth Sit in the Same Line on the Scale of operation Axis: Commercial
- Largest Commercial · 78%
- Fastest Commercial · 8.3%
- Moves most Commercial · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Preclinical | $3.50B | 5% | $5.54B | 4%-1 | 5.2% |
| Clinical | $11.90B | 17% | $20.79B | 15%-2 | 6.4% |
| Commercial | $54.60B | 78% | $112B | 81%+3 | 8.3% |
Commercial scale leads and also grows fastest, because launched products need repeated large lots every year and new approvals convert clinical programmes into commercial supply. Preclinical work is the smallest and slowest, since funding for early programmes is cyclical and much of it is done in small lots. By 2034 Commercial is still ahead, making this a shift in weight, not a change of leader.
By Process Type · 3 segments
Fed-Batch Held the Dominant Share of the Process type Segment in 2025
- Largest Fed-Batch · 65%
- Fastest Perfusion and Continuous · 14.7%
- Moves most Perfusion and Continuous · +11 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Batch | $14B | 20% | $16.63B | 12%-8 | 1.9% |
| Fed-Batch | $45.50B | 65% | $85.93B | 62%-3 | 7.3% |
| Perfusion and Continuous | $10.50B | 15% | $36.04B | 26%+11 | 14.7% |
Fed-batch leads because it is the established, well-validated route for most licensed antibodies, with known yields and a regulatory track record. Perfusion and continuous processing grows fastest as manufacturers seek higher productivity per unit of plant space, smaller footprints and steadier product quality for unstable molecules. Fed-Batch remains the largest line through 2034, so the axis changes in proportion, not in order.
By Bioreactor Technology · 2 segments
Single-Use Systems Holds the Largest Bioreactor technology Share and Is Still the Quickest to Grow
- Largest Single-Use Systems · 58%
- Fastest Single-Use Systems · 9.8%
- Moves most Single-Use Systems · +10 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single-Use Systems | $40.60B | 58% | $94.25B | 68%+10 | 9.8% |
| Stainless Steel Systems | $29.40B | 42% | $44.35B | 32%-10 | 4.7% |
Single-use systems lead because they cut cleaning validation, shorten changeover between products and suit the mid-sized lots typical of modern pipelines and contract sites. They also grow fastest as new plants are built with disposable flow paths from the start. Stainless steel stays important for the largest, long-running commercial lots at established plants. Single-Use Systems remains the largest line through 2034, so the axis changes in proportion, not in order.
By Therapeutic Area · 6 segments
Rare and Genetic Diseases Outpaces the Axis While Oncology Holds the Largest Share
- Largest Oncology · 34%
- Fastest Rare and Genetic Diseases · 13.3%
- Moves most Rare and Genetic Diseases · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Oncology | $23.80B | 34% | $45.74B | 33%-1 | 7.5% |
| Autoimmune and Inflammatory Diseases | $16.80B | 24% | $29.11B | 21%-3 | 6.3% |
| Infectious Diseases | $9.80B | 14% | $15.25B | 11%-3 | 5.2% |
| Metabolic Disorders | $8.40B | 12% | $16.63B | 12% | 7.9% |
| Neurology | $4.90B | 7% | $12.47B | 9%+2 | 10.9% |
| Rare and Genetic Diseases | $6.30B | 9% | $19.40B | 14%+5 | 13.3% |
Oncology leads because antibodies and related proteins are the backbone of many cancer regimens and treatment duration is long. Rare and genetic diseases grow fastest as gene and enzyme therapies reach approval, new orphan designations accumulate and small patient populations still justify specialised, high-value production runs. By 2034 Oncology is still ahead, making this a shift in weight, not a change of leader.
By Route of Administration · 4 segments
Scale in Injectable and Growth in Oral Define the Route of administration Axis
- Largest Injectable · 90%
- Fastest Oral · 12.9%
- Moves most Injectable · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Injectable | $63B | 90% | $121B | 87%-3 | 7.5% |
| Oral | $2.80B | 4% | $8.32B | 6%+2 | 12.9% |
| Inhalation | $2.10B | 3% | $5.54B | 4%+1 | 11.4% |
| Topical | $2.10B | 3% | $4.16B | 3% | 7.9% |
Injectable administration leads because large protein molecules break down in the gut and cross the skin poorly, so nearly all marketed biologics are infused or injected. Oral delivery grows fastest from a very small base as formulation work on permeation enhancers and protected peptide forms starts to produce late-stage candidates. The order does not change: Injectable is still largest in 2034, and what moves is how much it holds.
By End User · 4 segments
Pharmaceutical Companies Led by End user in 2025, with Contract Development and Manufacturing Organizations Growing Fastest
- Largest Pharmaceutical Companies · 48%
- Fastest Contract Development and Manufacturing Organizations · 12%
- Moves most Pharmaceutical Companies · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical Companies | $33.60B | 48% | $55.44B | 40%-8 | 5.7% |
| Biotechnology Companies | $18.90B | 27% | $40.19B | 29%+2 | 8.7% |
| Contract Development and Manufacturing Organizations | $14B | 20% | $38.81B | 28%+8 | 12% |
| Academic and Research Institutes | $3.50B | 5% | $4.16B | 3%-2 | 1.9% |
Pharmaceutical companies lead because they fund the largest commercial portfolios and place the biggest orders. Contract development and manufacturing organizations grow fastest as both large and small sponsors move capacity-heavy steps to specialist sites. Academic and research institutes remain the smallest buyers and grow slowly because purchases are tied to grant cycles. Pharmaceutical Companies remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3.6 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 1 of 5
- 2025 share 42%
- By 2034 38.4%
- Revenue $29.40B → $53.22B
In North America, 42% of global revenue puts 2025 at USD 29.4 billion with USD 53.22 billion projected for 2034. That makes it the first-largest region covered, in 2025 and again in 2034.
Its share moves to 38.4% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Monoclonal Antibodies largest at 46% of 2025 revenue, Cell and Gene Therapy fastest at 19.84%. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 91.8% of it, growing 1.8×.
- In region 1 of 2
- Of region 91.8%
- Of global 38.6%
- Revenue $27B → $48.70B
The largest single market in North America is the United States, at USD 27 billion in 2025 and USD 48.7 billion in 2034. Carrying 91.84% of the region in the base year, it sets North America's direction instead of merely contributing to it. Set against USD 29.4 billion and USD 53.22 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The molecule type pattern in the United States is the global one: 46% of 2025 revenue in Monoclonal Antibodies, 44% by 2034, against 19.84% growth in Cell and Gene Therapy taking it from 5% to 14%. Its 91.84% weight in North America means those movements carry straight into the regional totals. The United States carries its own molecule type breakdown in the full report.
In the United States, biologic active substances sit under the Food and Drug Administration, with the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research dividing oversight by product type. The route runs through the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. A sponsor files a Biologics License Application, and the active substance is described in its chemistry, manufacturing and controls section. An API supplier usually participates through a Drug Master File or a direct facility inspection. Manufacturing must follow current Good Manufacturing Practice, and the agency inspects sites in the country and abroad. Labelling and traceability follow the agency's requirements for the finished product.
The suppliers tracked in this study (Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG) compete in the United States across the molecule type lines above. Monoclonal Antibodies, at 46% of 2025 revenue, is where the volume sits, and Cell and Gene Therapy, growing at 19.84%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 1.9×.
- In region 2 of 2
- Of region 6.1%
- Of global 2.6%
- Revenue $1.80B → $3.40B
Canada is sized at USD 1.8 billion in 2025, rising to USD 3.4 billion by 2034; 2.57% of global revenue and 6.12% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 2nd-largest region covered — 1.8 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25.2%
- Revenue $18.90B → $34.93B
27% of the global biologics api market sits in Europe in 2025, worth USD 18.9 billion on the way to USD 34.93 billion by 2034. Among the five regions it ranks second by revenue in both years.
25.2% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Within the region the molecule type split tracks the global one; 46% of 2025 revenue in Monoclonal Antibodies, fastest growth of 19.84% in Cell and Gene Therapy. The full report breaks Europe out along every axis and by country.
Germany
The largest market in Europe, growing 1.7×.
- In region 1 of 3
- Of region 24.3%
- Of global 6.6%
- Revenue $4.60B → $8B
USD 4.6 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 8 billion by 2034. 24.34% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 18.9 billion in 2025 and USD 34.93 billion in 2034, it is the country the full report breaks out in detail.
Demand in Germany follows the molecule type mix reported at global level: Monoclonal Antibodies is the largest line at 46% of 2025 revenue, moving to 44% by 2034, while Cell and Gene Therapy grows fastest at 19.84% and takes its share from 5% to 14%. Its 24.34% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by molecule type separately.
Germany applies the European Union framework for medicinal products. Biologics reach the market through the centralised procedure at the European Medicines Agency, with the European Commission granting the authorisation. National oversight rests with the Paul-Ehrlich-Institut for most biological substances and with the Federal Institute for Drugs and Medical Devices for others. Active substance manufacturers must comply with EU Good Manufacturing Practice and hold a manufacturing authorisation from the competent state authority. A Qualified Person certifies each batch for release. Supplier dossiers follow the common technical document format, and the European Pharmacopoeia sets quality standards where a monograph exists.
The suppliers tracked in this study (Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG) compete in Germany across the molecule type lines above. The commercially relevant division is 46% of 2025 revenue in Monoclonal Antibodies, where the volume is, against 19.84% growth in Cell and Gene Therapy, where share moves. The commercial size of that position is USD 18.9 billion in 2025 and USD 34.93 billion by 2034, 27% of the global total in the base year.
Switzerland
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 16.4%
- Of global 4.4%
- Revenue $3.10B → $5.60B
Switzerland is sized at USD 3.1 billion in 2025, rising to USD 5.6 billion by 2034; 4.43% of global revenue and 16.4% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Ireland
3rd-largest in Europe, growing 1.7×.
- In region 3 of 3
- Of region 13.8%
- Of global 3.7%
- Revenue $2.60B → $4.40B
Ireland is sized at USD 2.6 billion in 2025, rising to USD 4.4 billion by 2034; 3.71% of global revenue and 13.76% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5.4 points of share by 2034, while revenue still grows 2.4×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 29.4%
- Revenue $16.80B → $40.74B
Asia Pacific holds 24% of the global biologics api market in 2025, worth USD 16.8 billion and reaches USD 40.74 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.
Share climbs to 29.4% by 2034, because it outgrows the market's 7.8%; the revenue added here is disproportionate to where the region started.
Monoclonal Antibodies leads here as it does globally, at 46% of 2025 revenue, and Cell and Gene Therapy again grows fastest at 19.84%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.7×.
- In region 1 of 3
- Of region 33.3%
- Of global 8%
- Revenue $5.60B → $15B
The largest single market in Asia Pacific is China, at USD 5.6 billion in 2025 and USD 15 billion in 2034. 33.33% of the region in the base year makes it the largest market here without making it the region. Set against USD 16.8 billion and USD 40.74 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in China follows the molecule type mix reported at global level: Monoclonal Antibodies is the largest line at 46% of 2025 revenue, moving to 44% by 2034, while Cell and Gene Therapy grows fastest at 19.84% and takes its share from 5% to 14%. Because the country carries 33.33% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by molecule type for China is reported separately in the full report.
China regulates biologics through the National Medical Products Administration and its Center for Drug Evaluation, under the Drug Administration Law. A biologic needs clinical trial approval followed by marketing authorisation, and imported products also need registration. Active substance suppliers are linked to the finished product through the associated review system, so the substance is evaluated alongside the drug application. Production sites must conform to the national Good Manufacturing Practice standard, and overseas sites may face inspection. The Chinese Pharmacopoeia provides the quality standards, and labelling must follow national instructions-for-use rules, in Chinese.
Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG are the suppliers covered in China. Volume sits in Monoclonal Antibodies at 46% of 2025 revenue; movement sits in Cell and Gene Therapy at 19.84% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 16.8 billion in 2025, reaching USD 40.74 billion by 2034 on the trajectory this study models.
South Korea
2nd-largest in Asia Pacific, growing 2.3×.
- In region 2 of 3
- Of region 23.2%
- Of global 5.6%
- Revenue $3.90B → $9B
Within Asia Pacific, South Korea accounts for 23.21% of regional revenue and 5.57% of the global total, worth USD 3.9 billion in 2025 and USD 9 billion by 2034.
Japan
3rd-largest in Asia Pacific, growing 1.8×.
- In region 3 of 3
- Of region 19.1%
- Of global 4.6%
- Revenue $3.20B → $5.80B
4.57% of global revenue is generated in Japan; USD 3.2 billion in 2025, reaching USD 5.8 billion in 2034, and 19.05% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered — 0.3 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 4 of 5
- 2025 share 4.2%
- By 2034 3.9%
- Revenue $2.94B → $5.41B
USD 2.94 billion of 2025 revenue is generated in Latin America, 4.2% of the global biologics api market on the way to USD 5.41 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 3.9%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Within the region the molecule type split tracks the global one; 46% of 2025 revenue in Monoclonal Antibodies, fastest growth of 19.84% in Cell and Gene Therapy. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 1.9×.
- In region 1 of 2
- Of region 44.2%
- Of global 1.9%
- Revenue $1.30B → $2.50B
Brazil is the largest market within Latin America, generating USD 1.3 billion in 2025 and projected to reach USD 2.5 billion by 2034. At 44.22% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 2.94 billion and USD 5.41 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Demand in Brazil follows the molecule type mix reported at global level: Monoclonal Antibodies is the largest line at 46% of 2025 revenue, moving to 44% by 2034, while Cell and Gene Therapy grows fastest at 19.84% and takes its share from 5% to 14%. Since 44.22% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-molecule type revenue for Brazil appears on its own in the full report.
In Brazil, the national health surveillance agency, ANVISA, regulates biologic medicines and their active substances. Biologics are registered either as new products or through a comparability pathway, and the dossier covers quality, nonclinical and clinical data. Active pharmaceutical ingredient makers, local or foreign, must be on file with the agency and follow its Good Manufacturing Practice rules, with inspections of foreign sites a routine part of the process. Importers need an operating authorisation. Labelling must appear in Portuguese and follow agency rules for package leaflets, and the Brazilian Pharmacopoeia applies where relevant.
Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG are the suppliers covered in Brazil. Two different problems sit on the same axis: holding Monoclonal Antibodies at 46% of 2025 revenue, and taking Cell and Gene Therapy while it grows at 19.84%. The commercial size of that position is USD 2.94 billion in 2025 and USD 5.41 billion by 2034, 4.2% of the global total in the base year.
Mexico
2nd-largest in Latin America, growing 1.9×.
- In region 2 of 2
- Of region 23.8%
- Of global 1%
- Revenue $0.70B → $1.30B
Within Latin America, Mexico accounts for 23.81% of regional revenue and 1% of the global total, worth USD 0.7 billion in 2025 and USD 1.3 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.3 points of share by 2034, while revenue still grows 2.2×.
- Rank 5 of 5
- 2025 share 2.8%
- By 2034 3.1%
- Revenue $1.96B → $4.30B
In Middle East and Africa, 2.8% of global revenue puts 2025 at USD 1.96 billion with USD 4.3 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.
Its share rises to 3.1% over the forecast period, because it outgrows the market's 7.8%; the revenue added here is disproportionate to where the region started.
Segment composition follows the global pattern: Monoclonal Antibodies largest at 46% of 2025 revenue, Cell and Gene Therapy fastest at 19.84%. Per-axis and per-country detail for Middle East and Africa sits in the full report.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.7×.
- In region 1 of 2
- Of region 23%
- Of global 0.6%
- Revenue $0.45B → $1.20B
22.96% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.45 billion, rising to USD 1.2 billion by 2034. Its 22.96% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Against regional totals of USD 1.96 billion in 2025 and USD 4.3 billion in 2034, it is the country the full report breaks out in detail.
Demand in Saudi Arabia follows the molecule type mix reported at global level: Monoclonal Antibodies is the largest line at 46% of 2025 revenue, moving to 44% by 2034, while Cell and Gene Therapy grows fastest at 19.84% and takes its share from 5% to 14%. Because the country carries 22.96% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own molecule type breakdown in the full report.
Saudi Arabia places biologics under the Saudi Food and Drug Authority, which handles registration and marketing authorisation for human medicines. A product is registered with a dossier in the common technical document format, and the active substance's quality and manufacturing details form part of it. The authority expects manufacturing sites to meet Good Manufacturing Practice, and it inspects or recognises inspections by trusted regulators. Foreign suppliers work through a licensed local agent or marketing authorisation holder. Labelling must carry Arabic and English text, and cold chain and storage conditions are checked as part of the approval.
Competition in Saudi Arabia runs between the suppliers this study tracks: Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG. Monoclonal Antibodies, at 46% of 2025 revenue, is where the volume sits, and Cell and Gene Therapy, growing at 19.84%, is where position changes hands over the forecast period. The commercial size of that position is USD 1.96 billion in 2025 and USD 4.3 billion by 2034, 2.8% of the global total in the base year.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 15.3%
- Of global 0.4%
- Revenue $0.30B → $0.60B
0.43% of global revenue is generated in South Africa; USD 0.3 billion in 2025, reaching USD 0.6 billion in 2034, and 15.31% of Middle East and Africa.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by molecule type, expression system, source, manufacturing mode, scale of operation, process type, bioreactor technology, therapeutic area, route of administration, end user, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Monoclonal Antibodies Volume and Cell and Gene Therapy Momentum
The field covered here is Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH and Bachem Holding AG.
Competition follows the molecule type split, not the regional one. The largest block of revenue is Monoclonal Antibodies: USD 32.2 billion in 2025 at 46% of the total, 44% in 2034. Incumbency there is expensive to challenge. Cell and Gene Therapy, compounding at 19.84% against 4.32% for Plasma-Derived Products, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, so a field of this size stays viable in a market of USD 70 billion.
Suppliers separate on validated large-scale cell culture capacity, a clean record with major regulators, and the ability to move a process between sites without losing yield. The largest players hold multi-site networks, long commercial supply contracts and deep experience filing chemistry, manufacturing and controls packages across several jurisdictions. Smaller and regional suppliers compete on speed to first lot, flexibility for short runs, specialist modalities such as viral vectors or conjugates, and closer technical support for early-stage developers. Supply reliability and capacity reservation terms often decide awards more than price for late-stage programmes.
Geographic reach is the other axis of competition. North America alone accounts for 42% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 27%.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Biologics API Market Companies Profiled
25 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Lonza Group AG(Switzerland)
- Samsung Biologics Co., Ltd.(South Korea)
- WuXi Biologics (Cayman) Inc.(China)
- Boehringer Ingelheim International GmbH(Germany)
- Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation)(Japan)
- Thermo Fisher Scientific Inc.(United States)
- Catalent, Inc.(United States)
- AGC Biologics(Japan)
- F. Hoffmann-La Roche Ltd (Genentech, Inc.)(Switzerland)
- Amgen Inc.(United States)
- Celltrion, Inc.(South Korea)
- Sandoz Group AG(Switzerland)
- Merck KGaA(Germany)
- Pfizer Inc.(United States)
- Biocon Biologics Ltd.(India)
- Rentschler Biopharma SE(Germany)
- Polpharma Biologics S.A.(Poland)
- Abzena Ltd.(United Kingdom)
- Emergent BioSolutions Inc.(United States)
- Dr. Reddy's Laboratories Ltd.(India)
- Gedeon Richter Plc(Hungary)
- Resilience (National Resilience, Inc.)(United States)
- Cytovance Biologics, Inc.(United States)
- Wacker Biotech GmbH(Germany)
- Bachem Holding AG(Switzerland)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Molecule Type, Expression System, Source, Manufacturing Mode, Scale of Operation, Process Type, Bioreactor Technology, Therapeutic Area, Route of Administration, End User), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 25 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Biologics API Market projected to reach?
USD 138.6 USD Billion by 2034, CAGR 7.8%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Monoclonal Antibodies is the largest line by molecule type, at 46% of revenue in 2025.
06Who are the key companies profiled?
Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH, Bachem Holding AG. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.